-
Mashup Score: 7
Nature – A phase I trial of a neoantigen-targeting personalized cancer vaccine led to durable and polyfunctional T cell responses and antitumour recognition, and was associated with no recurrence…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9Pfizer | Knock Out - 8 day(s) ago
Pfizer is fighting for 8 cancer breakthroughs by 2030.
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10
PURPOSESWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly diagnosed advanced biliary tract cancers (BTCs).METHODSPatients with …@SWOG 1815, a randomized phase 3 study comparing gem/cis/nab-paclitaxel versus gem/cis in BTC: no improvement in OS and additive toxicity with a triplet. Intriguing signal in locally advanced patients and GB cancer.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma - 10 day(s) ago
Abstract. Repeat element viral mimicry is a common feature in pancreatic ductal adenocarcinoma (PDAC) that require mechanisms to manage this repeat “viral” load and attenuate innate immune responses. Here, we show that the LINE-1 ORF1 protein (ORF1p) in PDAC cells plays a role in shielding repeat RNAs from activating a pathogen recognition receptor (PRR)-mediated antiviral response that is independent of retrotransposition. Suppression of ORF1p using short hairpin RNA induces innate immune responses through the dsRNA sensors RIG-I and MAVS. Low ORF1p PDAC cell lines have suppressed expression of PRRs demonstrating convergent mechanisms to suppress innate immune signaling. Localization of ORF1p in processing bodies (PBs) with the dsRNA helicase MOV10 were found important for these antiviral responses. Loss of ORF1p resulted in significant growth reduction in tumorspheres and mouse xenografts with an enriched epithelial cell state, and high ORF1p expression was associated with worsened s
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Stromal KITL/SCF maintains pancreas tissue homeostasis and restrains tumor progression - 10 day(s) ago
Abstract. Components of normal tissue architecture serve as barriers to tumor progression. Inflammatory and wound-healing programs are requisite features of solid tumorigenesis, wherein alterations to immune and non-immune stromal elements enable loss of homeostasis during tumor onset. The precise mechanisms by which normal stromal cell states limit tissue plasticity and tumorigenesis, and which are lost during tumor progression, remain largely unknown. Here we show that healthy pancreatic mesenchyme expresses the paracrine signaling molecule KITL, also known as stem cell factor, and identify loss of stromal KITL during tumorigenesis as tumor-promoting. Genetic inhibition of mesenchymal KITL in the contexts of health, injury, and cancer together indicate a role for KITL signaling in maintenance of pancreas tissue architecture, such that loss of the stromal KITL pool increased tumor growth and reduced survival of tumor-bearing mice. Together, these findings implicate loss of mesenchymal
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10
PURPOSESWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly diagnosed advanced biliary tract cancers (BTCs).METHODSPatients with …@SWOG 1815, a randomized phase 3 study comparing gem/cis/nab-paclitaxel versus gem/cis in BTC: no improvement in OS and additive toxicity with a triplet. Intriguing signal in locally advanced patients and GB cancer.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10
PURPOSESWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly diagnosed advanced biliary tract cancers (BTCs).METHODSPatients with …@SWOG 1815, a randomized phase 3 study comparing gem/cis/nab-paclitaxel versus gem/cis in BTC: no improvement in OS and additive toxicity with a triplet. Intriguing signal in locally advanced patients and GB cancer.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7
Nature – A phase I trial of a neoantigen-targeting personalized cancer vaccine led to durable and polyfunctional T cell responses and antitumour recognition, and was associated with no recurrence…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5
Nature – A phase I trial of a neoantigen-targeting personalized cancer vaccine led to durable and polyfunctional T cell responses and antitumour recognition, and was associated with no recurrence…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 21
Small bowel adenocarcinoma (SBA) is a rare malignancy marked with a poor prognosis. The cellular and proteomic heterogeneity within the tumor immune microenvironment (TIME) of SBA is a likely driver of prognosis, disease progression and response to therapy. We have addressed a major gap in knowledge of the TIME in SBA using highly multiplexed, protein imaging of the SBA tumor-immune ecosystem generating a comprehensive, single-cell level, spatial, proteomic atlas of TIME in > 600,000 cells from 136 tumor and matched normal samples from clinically and genomically annotated SBA patients (N=37). The SBA TIME Atlas informs on spatial distribution and interactions of tumor-intrinsic processes, diverse immune cell types, immune checkpoints, and vascularization. Enrichment of proliferating epithelial tissue, stem cells, and likely pro-tumor immune signatures in the tumor niche is contrasted by the representation of naive and early-effector T-cells in the epithelial compartments of adjacent no
Source: www.biorxiv.orgCategories: General Medicine News, Hem/OncsTweet-
Nice resource from @MDAndersonNews A spatially resolved single cell proteomic atlas of Small Bowel Adenocarcinoma https://t.co/hXpQyNiDNK @anilkorkut @michael_overman This preprint uses cyclic IF to interrogate a large series of archival small bowel adenocarcinomas and… https://t.co/69GpqOsxJr https://t.co/BrdSzvJvda
-
Link to the paper: A neoantigen vaccine generates antitumour immunity in renal cell carcinoma https://t.co/SAvZferMyG